Lahat N, Sobel E, Kraiem Z
Immunology Research Unit, Carmel Hospital, Haifa, Israel.
Cancer Res. 1993 Sep 1;53(17):3943-7.
Three intracellular signal transduction pathways have been found to be utilized by gamma-interferon (IFN-gamma) in the induction of HLA-DR in several cell types, mainly monocytes/macrophages and B-cells: the protein kinase A (PKA); Ca(2+)-calmodulin; and protein kinase C (PKC) pathways. In this study, we investigated the role of these pathways in IFN-gamma-induced HLA-DR expression in normal and neoplastic human thyroid cells. The PKA pathway seemed to inhibit both neoplastic and normal IFN-gamma-induced HLA-DR expression; addition of thyroid-stimulating hormone to normal thyroid cells, as well as 8-bromo cyclic AMP and forskolin to normal and neoplastic cells, reduced the amount of IFN-gamma-induced HLA-DR. Moreover, H-8, a PKA inhibitor, enhanced such IFN-gamma-induced HLA-DR expression. The calcium-calmodulin pathway does not seem to play a role in IFN-gamma-induced HLA-DR expression in normal and neoplastic thyrocytes, since the Ca-ionophore A23187, EGTA, and the calmodulin antagonist, W-7, neither induced HLA-DR nor showed any effect on HLA-DR expression induced by IFN-gamma. Alone, phorbol 12-myristate 13-acetate, a PKC activator, did not induce HLA-DR on thyroid cells. However, its addition to neoplastic cells together with IFN-gamma caused a synergistic elevation of the expressed HLA-DR, whereas it significantly inhibited IFN-gamma-induced HLA-DR in normal thyrocytes. TPA had to be added before or together with IFN-gamma for optimal function. If added more than 6 h after IFN-gamma, TPA was not effective. An inactive TPA analogue did not affect HLA-DR induction, while an active analogue mimicked TPA. Staurosporine, a PKC inhibitor, reduced the TPA enhancing effect in neoplastic thyrocytes and cancelled TPA inhibition in normal cells. Moreover, when added to IFN-gamma without TPA in normal thyroid cells, staurosporine increased 3- to 4-fold the amount of HLA-DR. Thus, in normal thyroid cells the PKC pathway is activated by IFN-gamma and inhibits HLA-DR expression. In neoplastic thyrocytes, although IFN-gamma does not induce HLA-DR via PKC, this pathway augments HLA-DR expression.
已发现γ干扰素(IFN-γ)在几种细胞类型(主要是单核细胞/巨噬细胞和B细胞)中诱导HLA-DR表达时利用了三种细胞内信号转导途径:蛋白激酶A(PKA);Ca(2+)-钙调蛋白;以及蛋白激酶C(PKC)途径。在本研究中,我们调查了这些途径在正常和肿瘤性人甲状腺细胞中IFN-γ诱导的HLA-DR表达中的作用。PKA途径似乎抑制肿瘤性和正常的IFN-γ诱导的HLA-DR表达;向正常甲状腺细胞中添加促甲状腺激素,以及向正常和肿瘤性细胞中添加8-溴环磷酸腺苷和福斯可林,均可减少IFN-γ诱导的HLA-DR的量。此外,PKA抑制剂H-8增强了这种IFN-γ诱导的HLA-DR表达。钙-钙调蛋白途径似乎在正常和肿瘤性甲状腺细胞中IFN-γ诱导的HLA-DR表达中不起作用,因为钙离子载体A23187、乙二醇双乙醚二胺四乙酸(EGTA)和钙调蛋白拮抗剂W-7既不诱导HLA-DR,也对IFN-γ诱导的HLA-DR表达没有任何影响。单独使用PKC激活剂佛波醇12-肉豆蔻酸酯13-乙酸酯(TPA)不会在甲状腺细胞上诱导HLA-DR。然而,将其与IFN-γ一起添加到肿瘤性细胞中会导致表达的HLA-DR协同升高,而在正常甲状腺细胞中它会显著抑制IFN-γ诱导的HLA-DR。TPA必须在IFN-γ之前或同时添加才能发挥最佳作用。如果在IFN-γ之后6小时以上添加TPA,则无效。无活性的TPA类似物不影响HLA-DR的诱导,而活性类似物则模拟TPA的作用。PKC抑制剂星形孢菌素降低了肿瘤性甲状腺细胞中TPA的增强作用,并消除了TPA在正常细胞中的抑制作用。此外,在正常甲状腺细胞中,当在没有TPA的情况下添加到IFN-γ中时,星形孢菌素使HLA-DR的量增加了3至4倍。因此,在正常甲状腺细胞中,PKC途径被IFN-γ激活并抑制HLA-DR表达。在肿瘤性甲状腺细胞中,尽管IFN-γ不通过PKC诱导HLA-DR,但该途径会增强HLA-DR表达。